Enabling Next-Generation Biodefense Solutions
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Our instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats.
The company’s innovative and patent-pending time of flight mass spec technology dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems currently deployed for biodefense applications. Our instrument’s high sensitivity enables fully-automated and near real-time identification of bio-threats in operational environments.
Our approach leverages decades of development surrounding the molecular basis of pathogenic organisms and biological toxins.
The U.S. Department of Defense funded initial development of Zeteo’s miniaturized, low-cost, low-power mass spectrometer technology for the identification of aerosolized bio-threats in near real-time. The Department of Homeland Security is funding advanced development and maturation of the systems. One current application focus is critical infrastructure protection.
Cost-Effective Patient Screening for Infectious Disease
Two billion people are infected with TB globally and it is the leading cause of death by infectious disease.
– World Health Organization
Preliminary measurements demonstrate that we can rapidly and non-invasively screen populations to find individuals likely to have tuberculosis (TB), and at a cost of pennies per person.
Because of the high prevalence of TB globally, the emergence of highly drug-resistance strains, and the lack of an effective vaccine, mass patient screening, or “active case finding,” is perhaps the most effective near-term strategy to control the TB epidemic.
Zeteo’s innovative and patent-pending time-of-flight mass spec technology dramatically lowers instrument cost and size relative to the MALDI instruments used globally in the clinical diagnostics market today. Our instrument’s high sensitivity enables near real-time screening for disease at the point-of-care, without culturing or other means of signal amplification.
Zeteo Tech initiated this technology development under support from the Bill and Melinda Gates Foundation. Currently efforts are funded by NIH NAIAD to accelerate the development and translation of innovative new products for patient screening of multiple pathogens based on respired air.
2020 Tibbetts Award Winner. – Zeteo Tech, Inc.
We are proud to announce that Zeteo Tech was included in the U.S. Small Business Administration’s list of 38 companies recognized as winners of the prestigious 2020 Tibbetts Award for their accomplishments in creating cutting-edge technologies. The Tibbetts Awards, named after Roland Tibbetts, the founder of the SBIR Program, honors these awardees for the exceptional successes they achieved through SBA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs.
“For nearly four decades, the SBIR and STTR programs have been assisting small businesses with launching ideas from conception to market. The Tibbetts Awards highlight our nation’s next generation of competitive creators who help push the U.S. economy into the future,” said SBA Administrator Jovita Carranza. “SBA continues to play a key role in administering these research and technology funding programs, providing ‘seed money’ to help our nation’s greatest and most innovative research entrepreneurs start, grow and transition into high-growth companies. The companies and the technologies they create played a unique role in job creation, the building of new industries and communities and addressing the nation’s most pressing challenges.”